Anhui Golden Sun Biochemical Pharmaceutical

Anhui Golden Sun Biochemical Pharmaceutical Co., Ltd., a subsidiary of Jinzi Seed Liquor Co., Ltd. (a listed company), was established in January 2000 with a registered capital of 30 million yuan. The company currently has 226 employees, including 119 with a college degree or higher, and 21 employees with intermediate or higher titles such as senior engineers, engineers, licensed pharmacists, and chief pharmacists.The company mainly engages in the production and sales of tablets, small-volume injections, hard capsules, active pharmaceutical ingredients, formulations of second-class psychotropic drugs, and chemical products (excluding hazardous chemicals). Its main products include Compound Musk Injection, Compound Cerebroprotein Hydrolysate Tablets, β-Thymidine, Dexamethasone Acetate Tablets, Bone Healing and Muscle Continuation Capsules, Pancreatin Enteric-Coated Capsules, and Prednisone Acetate Tablets.The company operates four workshops: an injection workshop, a solid dosage workshop, and an extraction workshop. Currently, it has 51 varieties and 86 specifications. The annual production capacity is 4 billion tablets for tablets, 100 million capsules for capsule agents, 150 million small-volume injections, 150 tons of synthetic active pharmaceutical ingredients, and 200 tons for the extraction workshop. In 2022, the company achieved revenue of 156 million yuan and a profit of 13 million yuan.